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different biological functions, as indicated by their specific expression patterns. 9, 10 ER-beta is expressed in both human breast tumours 11 and chemically transformed human breast epithelial cells. 12 ER-beta splice variants have also been discovered in some breast tumours. 13, 14 Besides their different physiological functions, Jarvinen et al. suggested that ER-beta was expressed in 75% of ER-alpha-positive and PRpositive breast cancer tumours, and was likely to respond to hormonal therapy. 15 Some studies suggested that wild-type ER-beta tended to be a good prognostic indicator, 16, 17 whereas othersr eached contrary conclusions. 18 These studies illustrated that the relationship between ER-beta and ER-alpha was complicated and demanded further research.
Human epidermal growth factor receptor 2 (HER2, neu or c-erb-B2) is a ligand orphan receptor. HER2 activates several downstream signaling cascades and new downstream HER2 signaling proteins remain to be identified. 19 In preclinical studies, HER2 overexpression was found to be associated with a variety of features that make tumour cells more aggressive. 20, 21 In clinical studies, amplification or overexpression of HER2 in tumour cells was associated with poor clinical outcome. 22, 23 Recent studies demonstrated that HER2 could regulate the function of ER through the Ras/MAPK signaling pathway. HER2 overexpression activates the Ras/MAPK signaling pathway in breast tumour cell lines and carcinomas. 24, 25 Clinical studies also suggested that HER2/neu were related to the ER status in human breast cancer. [26] [27] [28] [29] [30] However, few studies have reported the relationship between ER-beta and HER2, especially in oriental people. In this study, we investigated the expression of ER-beta and HER2 in 308 cases of human breast cancer in China, evaluated their prognostic values in the breast cancer patients and indicated the possible clinical relationship between ER-beta and HER2 expression.
Patients and Methods

Patients
Tumour specimens from 308 patients (mean age, 58 yr; range, 30-79 yr) with no sign of distant metastasis and who underwent surgery for primary breast cancer from 1993-1998 [modified mastectomy, 217 patients, breast-conserving lumpectomy, 91 patients] at Shanghai Cancer Hospital in Shanghai, China were evaluated. Tumour specimens were submitted to the Laboratory of Hormone Receptors for steroid receptor analysis. Women with positive lymph nodes generally received adjuvant chemotherapy (164 patients); 109 patients received hormonal therapy (tamoxifen), and 7 patients were irradiated. The median follow-up for patients was 48 months. A computerized database containing updated clinicopathological information was established for statistical analysis. The study received Institutional Ethics Committee approval.
Immunohistochemistry (IHC)
The following primary antibodies and dilutions were used: anti-ERß (Ab-1, Oncogene), rabbit polyclonal antibody; (Novocastra); an affinity-purified rabbit polyclonal antiserum raised against an intracellular epitope of the human HER-2 molecule (specification sheet K5205, Dako). Both antibodies were diluted at 1:5000. Five-µm -thick sections were cut and mounted on SuperFrost Plus slides. Sections were left unbaked until immediately before use when they were baked for 1 hour at 60°C. After baking, sections were deparaffinized by three changes of xylene and rehydrated through graded alcohols into water. Heatinduced epitope retrieval was performed by boiling sections in citrate buffer pH 6.0 (pH 6.2 for ERß) for 15 min on a laboratory hotplate. After boiling, sections were removed from the hotplate, allowed to cool at room temperature for 20 min, and were then rinsed thoroughly with water. Sections were then placed in 3% hydrogen peroxide for 15 min at room temperaQui et al. Primary breast cancer ture to block endogenous peroxidase, washed with water, and placed in PBS (Sigma). Sections were incubated with Power Block (Biogenex) nonspecific blocking reagent for another 10 min at room temperature to reduce nonspecific staining, washed with water, and placed in PBS. After that, sections were incubated with normal goat serum at 1:50 (Vector, Burlingame, CA) for 15 min at room temperature. The goat serum was then shaken off and sections were incubated with primary antibodies overnight at 4°C. After overnight incubation, each section received 20 sec washing with PBS, 20 sec washing with Biogenex Optimax detergent wash solution, followed by 10 min washing in PBS on a rotator. Solutions were changed for every eight slides. After washing, sections were incubated with Biogenex Multilink secondary antibody at a dilution of 1:20 for 20 min at room temperature. Sections were again washed according to the protocol described above. Slides were stained using the ABC elite kit (Vector Laboratories) with diaminobenzidine according to the manufacturer's protocol. All ER-beta and PR immunoreactive cells were considered positive regardless of the staining intensity, and the fraction of positive cells was recorded. A case was considered positive if > 10% cells were stained. Immunostaining was analyzed with an Olympus Corp. BX-50 microscope, and pictures were taken with an Olympus Corp. Oly 760 video camera. 31, 32 Each HER2 immunohistochemical staining experiment included a set of control slides. For the negative control section the primary antibody was replaced with an irrelevant, isotype-matched antibody, to control for nonspecific binding of the secondary antibody reagent. The positive control slide consisted of sections of cell blocks of the three breast cancer cell lines SKBR3, MDA-MB-175 and MDA-MB-231, which express 2.4 million, 92,000 and 22,000 HER-2 receptor molecules, by Scatchard analysis, respectively. These receptor numbers correspond to IHC HER-2 scores of +++, + and 0. 33 A score of ≥ + or above was counted as positive.
The staining results were read by a group of senior pathologists. In each case, 2,000 tumuor cells were counted from 10 randomly selected areas, ensuring that the whole section was scanned. All negative cases were repeated for eliminating false negative and confirming true negative.
Statistical Analysis
Life tables were calculated according to the KaplanMeier method. DDFS was computed from the date of diagnosis to the occurrence of metastases outside the locoregional area or to death from breast cancer, whichever came first. Breast cancer-specific survival was calculated from the date of diagnosis until death from breast cancer. Patients who died from an intercurrent cause were censored at the date of death. Survival curves were compared using the Log-rank test. Multivariate survival analyses were performed using the following covariates: (a) grade (well differentiated, 0; moderately or poorly differentiated, 1, because moderately and poorly differentiated cancers had similar outcome); (b) ER and PgR status (positive or borderline, 1; negative, 0); (c) HER2 positive status (negative, 0; positive, 1); (e) histological type (lobular or special, 0; ductal, 1; the lobular and special types were associated with similar outcome); and (f) tumour size in millimeters as a continuous variable. The final multivariate model was constructed using backward Cox stepwise proportional hazards regression, and a P < 0.05 was adopted as the limit for inclusion of a covariate. All P values are two sided.
Results
Demographics
308 patients were studied. The basic demographics of this group and the pathological characteristics are shown in Tables 1 and 2 , respectively. The median age was 58 yr (range 30-79 yr). 
Expression of ER-beta and HER2
The tumours were divided into three main histological types: invasive ductal carcinoma, invasive lobular carcinoma and adenocarcinoma. ER-beta positive cells were stained brown by IHC staining in the nuclei, while HER2 positive cells were stained brown by IHC staining on the cytomembrane. (Fig. 1) .
Association of ER-beta expression with other prognostic parameters
123 patients (40%) were ER-beta positive by IHC. ER-beta positive status was associated with ER-alpha (P=0.023), poor cell differentiation, grade 3 (P=0.010) and menopause age < 45 yr (P=0.031). ER-beta positive status has no association with PR status, lymph node or tumour size. (Table 3) .
Association of HER2 positive with other prognostic parameters except estrogen receptors
58 patients (18.5 %) were HER2 positive by IHC. HER2 positive associates with poor cell differentiation of grade 3 ( .1%, P=0.001) and ≥3cm tumour size (63.2%, P=0.011). However, it has no association with PR status lymph node, or menopausal status (Table 4).
Association of estrogen receptors with HER2 positive
ER-beta expression was associated with the HER2 positive (P=0.018). In 58 HER2 positive patients, 44 were ER-beta positive, while only 14 were ERbeta negative. ER-alpha positive was not associated with HER2 positive. In addition, subgroups of ERbeta positive and ER-alpha negative (ER-beta +/ ER-alpha ) were associated with HER2 positive (P<0.001) ( Tables 1, 3 4 not due to previous chemotherapy. ‡ ER-beta +/ER-alpha -subgroups of ER-beta positive in the absence of ER-alpha. ER-beta +/ER-alpha + subgroup of ER-beta positive in the presence of ER-alpha. † Menopause age younger than 45 years Tables 1, 3 4 not due to previous chemotherapy. ‡ ER-beta +/ER-alpha -subgroups of ER-beta positive in the absence of ER-alpha. ER-beta +/ER-alpha + subgroup of ER-beta positive in the presence of ER-alpha. † Menopause age younger than 45 years Tables 1, 3 4 not due to previous chemotherapy. ‡ ER-beta +/ER-alpha -subgroups of ER-beta positive in the absence of ER-alpha. ER-beta +/ER-alpha + subgroup of ER-beta positive in the presence of ER-alpha. † Menopause age younger than 45 years Tables 1, 3 4 not due to previous chemotherapy. ‡ ER-beta +/ER-alpha -subgroups of ER-beta positive in the absence of ER-alpha. ER-beta +/ER-alpha + subgroup of ER-beta positive in the presence of ER-alpha. 
ER-beta expression and HER2 positive are associated with poorer survival
Univariate analysis of ER-beta positive status indicated its association with poorer OS compared with ER-beta negative sub-group (P=0.003) (Fig. 2A) . HER2 positive showed association with poorer OS compared with HER2 negative sub-group (P<0.001) in univariate analysis (Fig. 2B) .
Outcome Survival of subgroups of ER-beta and HER2
We then analyzed the OS of four subgroups: ER-beta positive and HER2 negative ER-beta +/HER2 ; ER-beta positive and HER2 positive (ER-beta +/ HER2 ; ER-beta negative and HER2 negative (ERbeta /HER2 ); ER-beta negative and HER2 positive (ER-beta /HER2
. In the subgroup of ER-beta positive patients, the OS of HER2 negative patients was longer than that of HER2 positive patients (P<0.001) (Fig. 3A) and, in the subgroup of ER-beta negative patients, the OS of HER2 negative patients was longer than that of HER2 positive patients (P<0.001) (Fig. 3B) . However, in the subgroup of HER2 positive patients, the OS of ER-beta negative patients was not different from that of ER-beta positive patients (Fig. 3C) . In the subgroup of HER2 negative patients, the OS of ER-beta negative patients was not different from that of ER-beta positive patients (P=0.541) (Fig. 3D) .
DDFS of subgroups of ER-beta and HER2
The DDFSs of the above four subgroups were also analyzed. In the subgroup of ER-beta positive patients, the DDFS of HER2 negative patients was longer than that of HER2 positive patients (P<0.001) (Fig. 4A) . In the subgroup of ER-beta negative patients, the DDFS of HER2 negative patients was longer than that of HER2 positive patients (P<0.001) (Fig. 4B) . In the subgroup of HER2 positive patients, the DDFS of ER-beta negative patients was no longer than that of ER-beta positive (Fig. 4C) . In the subgroup of HER2 negative patients, the DDFS of ERbeta negative patients was longer than that of ER-beta positive patients (P=0.005 (Fig. 4D ).
Discussion
We found that ER-beta positivity was associated with ER-alpha positivity, poor cell differentiation and menopausal age < 45 yr, but was not associated with PR We investigated ER-beta status and HER2 positive in 308 patients of breast cancer. ER-beta positivity was associated with HER2 positivity in breast cancer (Tables 3 and 4) . HER2 positivity was a prognostic factor in breast cancer, and ER-beta positivity showed poorer outcome than ER-beta negativity in univariate analysis ( Fig. 2A) . ER-beta was not an independent prognostic indicator of breast cancer but was associated with a shorter survival time by univariate analysis ( Fig. 2A) . Considering that ER-beta positivity was likely accompanied with HER2 positivity, we hypothesized that the poorer survival of ER-beta positive patients would be due to HER2 positivity. We then analyzed the survival of subgroups of patients: ERbeta +/HER2 ; ER-beta +/HER2 ; ER-beta /HER2
; ER-beta /HER2 . HER2 positive was s associated with poorer OS in either ER-beta positive or ER-beta negative subgroups (Figs. 3A and 3B ). In either HER2 positive or HER2 negative subgroups, however, ERbeta positive was not associated with poorer OS (Figs.  3C and 3D ). These results implied that ER-beta positive would not be associated with poorer OS when the interference of HER2 positive was ruled out. Analysis of DDFS figured similar results for HER2 positive in either ER-beta positive or ER-beta negative subgroups (Figs. 4A and 4B ). ER-beta positive was associated with poorer DDFS in HER2 negative subgroup (Fig.  4D) , implying that ER-beta might be related to metastasis of breast cancer. In addition, the subgroup of ERbeta positive accompanied with ER-alpha negative (ER-beta +/ER-alpha ) was associated with HER2 positive.
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ER-alpha and ER-beta are the major mediators of a variety of biological functions of estrogens. 34, 35 There are many reports of ER-beta in basic and clinical research. Multiple biological functions as well as the prognostic value of ER-beta have been reported. 17, 36 Jarvinen et al. reported that ER-beta positive associated with both ER-alpha positive and PR positive in breast cancer tumours. 15 The fact that their results are partly different from ours may be due to racial diversity. Several recent papers have suggested that HER2 expression in breast carcinomas may be an indicator of resistance to hormonal (predominantly tamoxifen) therapy. 37, 38 This unfortunate resistance to endocrine therapy could be partly due to crosstalk between the ER and EGFR/HER2 and/or their downstream effectors. HER2 gene amplified in breast cancer cells partially restored the ability of tamoxifen to inhibit estradiol-stimulated ER reporter activity. 39, 40 Since ER-beta exerts multiple effects in the estrogen signaling pathway, the relation between ER-beta and HER2 should attract researchers. However, there are few papers concerning ER-beta together with HER2. In 2001, ER-beta positive in the absence of ERalpha associated with high expression of Ki67 was found in breast cancer. 41, 42 This result and the present study imply that, in the absence of ER-alpha, ER-beta plays a different role in breast cancer from that in the presence of ER-alpha, and this role might relate to HER2 and Ki67.
In conclusion, we have shown that ER-beta positive status is associated with HER2 positivity, poor cell differentiation and menopause age ≤45 years. HER2 positive status is associated with poor cell differentiation, ≥3cm tumour size and ER-beta positive status. ER-beta positive status and HER2 positivity showed association with poorer OS. When interference of HER2 positivity was ruled out, ER-beta positive status was associated with poorer DDFS but not OS, which implied that ER-beta might be related to the metastasis of breast cancer.
